Recruiting

Observational Study

Sponsor:

Ray Therapeutics, Inc.

Code:

NCT07502664

Conditions

Retinitis Pigmentosa

Stargardt Macular Dystrophy

Stargardt Disease

Geographic Atrophy From Age-related Macular Degeneration

X-linked Retinoschisis

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

The Vision Research and Assessment Institute (VRAI) was established with the purpose of serving as a testing facility for efficacy endpoints for patients with Low Vision.

The mission of the VRAI is to enable the highest quality, standardized efficacy testing of patients with visual impairment.

The VRAI facilitates the development and refinement of existing endpoints specifically for testing patients with Low Vision.

Conditions

Retinitis Pigmentosa

Stargardt Macular Dystrophy

Stargardt Disease

Geographic Atrophy From Age-related Macular Degeneration

X-linked Retinoschisis

Study ID

NCT07502664

Start date

Feb 19, 2026

Status verified date

Mar, 2026

Completion date

Feb, 2027

Anticipated

Primary completion date

Feb, 2027

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • Diagnosis of bilateral retinitis pigmentosa (RP) or other retinal dystrophies impacting peripheral vision as confirmed from previous eye examination records
  • Best-corrected visual acuity between 20/200 to HM in at least one eye.
  • Reasonably fluent in English or Spanish

Exclusion Criteria:

  • Cognitive impairment, memory loss or dementia sufficient in severity to preclude informed consent or in the opinion of the investigator would prevent satisfactory completion of some or all of the testing.
  • Any circumstance that in the opinion of the investigator, would interfere with participation in, or compliance with the study protocol
  • Current pregnancy as reported by patient

Study Design

Enrollment

25 participants

Anticipated

Interventions and Outcome Measures

Arms

Retinitis Pigmentosa

Up to 25 patients with Retinitis Pigmentosa

Other Retinal Dystrophies

Up to 25 patients with Other Retinal Dystrophies

Primary outcome measure

  • Operational feasibility of testing moderate to profound vision impaired patients with various retinal dystrophies on a battery of visual assessments [ Time Frame: 3 months ]

Central Contacts and Locations

Central contacts

Reem Jaber, MS, CGC

949-264-3793info@vr-ai.com

Locations

Vision Research and Assessment Institute

Recruiting

Irvine, California, United States, 92614

Contacts

Reem Jaber, MS, CGC

949-264-3793info@vr-ai.com

More Information

Sponsor

Ray Therapeutics, Inc.

Last update posted

Mar 31, 2026

Last verified

Mar, 2026

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-10. This information was provided to ClinicalTrials.gov by Ray Therapeutics, Inc. on 2026-03-31.